Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure.

Sabrina Storgaard Sørensen Line Hust Storgaard Ulla Møller Weinreich

Published in: ClinicoEconomics and outcomes research : CEOR (2021)

This is the first cost-effectiveness study on domiciliary HFNC in Europe. The findings demonstrate that long-term domiciliary HFNC treatment is very likely to be a cost-effective addition to usual care for COPD patients with chronic respiratory failure. The results must be interpreted in light of the uncertainty associated with the indirect estimation of health state utilities.

Keyphrases

respiratory failure
extracorporeal membrane oxygenation
mechanical ventilation
healthcare
chronic obstructive pulmonary disease
public health
lung function
acute respiratory distress syndrome
intensive care unit
cystic fibrosis
pain management
smoking cessation
health insurance
chronic rhinosinusitis